Karmugi Balaratnam

机构：University of Toronto, Princess Margaret Cancer Centre

发表论文 38 篇 · 总被引 246 次 · h-index 9

代表论文

• Polygenic risk score for ulcerative colitis predicts immune checkpoint inhibitor-mediated colitis (2024 · Nature Communications · 被引 35)
• Real-World Treatment Sequencing, Toxicities, Health Utilities, and Survival Outcomes in Patients with Advanced ALK-Rearranged Non-Small-Cell Lung Cancer (2022 · Clinical Lung Cancer · 被引 23)
• EGFR mutation prevalence, real-world treatment patterns, and outcomes among patients with resected, early-stage, non-small cell lung cancer in Canada (2022 · Lung Cancer · 被引 18)
• Treatment patterns and outcomes in early-stage ALK-rearranged non-small cell lung cancer (2022 · Lung Cancer · 被引 12)
• Germline prediction of immune checkpoint inhibitor discontinuation for immune-related adverse events (2025 · Journal for ImmunoTherapy of Cancer · 被引 9)
• Treatment patterns and outcomes in KRAS‐positive advanced NSCLC patients previously treated with immune checkpoint inhibitors: A Canada-wide real-world, multi-center, retrospective cohort study (2024 · Lung Cancer · 被引 9)